We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Caliper Life Sciences Grants Multi-Year Imaging Patent License
News

Caliper Life Sciences Grants Multi-Year Imaging Patent License

Caliper Life Sciences Grants Multi-Year Imaging Patent License
News

Caliper Life Sciences Grants Multi-Year Imaging Patent License

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Caliper Life Sciences Grants Multi-Year Imaging Patent License"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Caliper Life Sciences, Inc. has announced that Novartis has signed a multi-year license to Caliper's patented non-invasive optical imaging methods.

Non-invasive optical imaging allows scientists to visualize, track and quantify biological processes at the molecular level in living animals with high throughput and relatively low cost.

Caliper can provide commercial and academic customers with a selection of in vivo offerings including imaging systems, reagents, applications, proprietary methods and services that improve drug discovery and development efforts.

"This multi-year agreement further validates the importance and relevance of Caliper's optical imaging technology and intellectual property," said Kevin Hrusovsky, chief executive officer, Caliper Life Sciences.

"More than 70% of major pharmaceutical companies, and 60% of major biotech companies, now hold a license to the Caliper Optical Imaging Patent Suite, and smaller biotechs are following suit in increasing numbers."

Hrusovsky added, "Our recent notification of allowance of patent claims for conjugate fluorescence imaging methods from the U.S. Patent and Trademark Office has significantly increased the value of Caliper's intellectual property estate and complements Caliper's aggressive investment in conjugate probe development."

Advertisement